002932 *ST明德
已收盘 09-08 15:00:00
资讯
新帖
简况
*ST明德（002932）2026年中报简析：增收不增利，公司应收账款体量较大
证券之星 · 08-29
*ST明德（002932）2026年中报简析：增收不增利，公司应收账款体量较大
图解*ST明德中报：第二季度单季净利润同比下降232.98%
证券之星 · 08-28
图解*ST明德中报：第二季度单季净利润同比下降232.98%
*ST明德(002932.SZ)：暂未直接开展脑机接口业务
中金财经 · 08-27
*ST明德(002932.SZ)：暂未直接开展脑机接口业务
*ST明德：关于现金使用策略，公司始终兼顾经营需求、战略发展及全体股东利益
证券之星 · 08-27
*ST明德：关于现金使用策略，公司始终兼顾经营需求、战略发展及全体股东利益
*ST明德：以数据为核心、AI医疗技术为引擎
证券之星 · 08-27
*ST明德：以数据为核心、AI医疗技术为引擎
*ST明德：已制定《2026年度估值提升计划》
证券之星 · 08-27
*ST明德：已制定《2026年度估值提升计划》
*ST明德：公司已于6月完成股份回购计划
证券之星 · 08-27
*ST明德：公司已于6月完成股份回购计划
*ST明德：公司长期聚焦体外诊断主业发展
证券之星 · 08-27
*ST明德：公司长期聚焦体外诊断主业发展
*ST明德：公司正逐步实现从体外诊断产品供应商向智慧诊疗一体化解决方案服务商的战略转型
证券之星 · 08-27
*ST明德：公司正逐步实现从体外诊断产品供应商向智慧诊疗一体化解决方案服务商的战略转型
*ST明德(002932)7月31日股东户数1.48万户，较上期减少1.11%
证券之星 · 08-27
*ST明德(002932)7月31日股东户数1.48万户，较上期减少1.11%
*ST明德：现阶段不存在出让上市公司控制权的相关考量与筹划安排
证券之星 · 08-27
*ST明德：现阶段不存在出让上市公司控制权的相关考量与筹划安排
*ST明德：整合安排详见公司于《武汉明德生物科技股份有限公司重大资产购买报告书》中披露的相关内容
证券之星 · 08-27
*ST明德：整合安排详见公司于《武汉明德生物科技股份有限公司重大资产购买报告书》中披露的相关内容
*ST明德：公司重点研发项目及进展请查阅公司定期报告
证券之星 · 08-27
*ST明德：公司重点研发项目及进展请查阅公司定期报告
*ST明德：公司研发支出采用费用化处理是公司基于会计谨慎性原则的账务处理
证券之星 · 08-27
*ST明德：公司研发支出采用费用化处理是公司基于会计谨慎性原则的账务处理
*ST明德：稳步推进对湖南蓝怡治理、财务、业务、供应链及团队一体化整合
证券之星 · 08-27
*ST明德：稳步推进对湖南蓝怡治理、财务、业务、供应链及团队一体化整合
*ST明德：本次收购前必凯尔累计向原股东分红近2亿元
证券之星 · 08-27
*ST明德：本次收购前必凯尔累计向原股东分红近2亿元
*ST明德：控股子公司的营业收入全部计入合并报表营业收入
证券之星 · 08-27
*ST明德：控股子公司的营业收入全部计入合并报表营业收入
*ST明德：公司正根据整体战略规划，对包括品牌展示在内的资源配置进行统筹优化
证券之星 · 08-27
*ST明德：公司正根据整体战略规划，对包括品牌展示在内的资源配置进行统筹优化
*ST明德：公司现有糖化血红蛋白系列产品主要面向医疗机构、体检中心等专业机构用户
证券之星 · 08-27
*ST明德：公司现有糖化血红蛋白系列产品主要面向医疗机构、体检中心等专业机构用户
*ST明德：呼吸道相关检测秋冬季需求相对较高
证券之星 · 08-27
*ST明德：呼吸道相关检测秋冬季需求相对较高
加载更多
公司概况
公司名称：
武汉明德生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2018-07-10
主营业务：
武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公司的主要产品是体外诊断试剂、诊断仪器。
发行价格：
20.45
{"stockData":{"symbol":"002932","market":"SZ","secType":"STK","nameCN":"*ST明德","latestPrice":15.6,"timestamp":1788851010000,"preClose":15.3,"halted":0,"volume":804943,"delay":0,"changeRate":0.0196,"floatShares":156000000,"shares":233000000,"eps":-0.2186,"marketStatus":"已收盘","change":0.3,"latestTime":"09-08 15:00:00","open":15.31,"high":15.6,"low":15.31,"amount":12468900,"amplitude":0.019,"askPrice":15.6,"askSize":212,"bidPrice":15.57,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.2186,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.3,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":16.07,"lowLimit":14.54,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":232520957,"isCdr":false,"pbRate":0.66,"roa":"--","roe":"--","epsLYR":-0.07,"committee":-0.260173,"marketValue":3627000000,"turnoverRate":0.0052,"status":0,"floatMarketCap":2435000000},"requestUrl":"/m/hq/s/002932/","defaultTab":"news","newsList":[{"id":"2663016150","title":"*ST明德（002932）2026年中报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016150","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663016150?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:30","pubTimestamp":1787956205,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期*ST明德发布2026年中报。截至本报告期末，公司营业总收入1.41亿元，同比上升1.54%，归母净利润-2186.76万元，同比下降274.98%。按单季度数据看，第二季度营业总收入7076.41万元，同比上升2.07%，第二季度归母净利润-2149.02万元，同比下降232.98%。本报告期*ST明德公司应收账款体量较大，当期应收账款占最新年报营业总收入比达142.39%。本次财报公布的各项数据指标表现一般。本文数据来源于*ST明德2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900011458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080863","title":"图解*ST明德中报：第二季度单季净利润同比下降232.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662080863?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:04","pubTimestamp":1787857492,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德2026年中报显示，上半年度公司主营收入1.41亿元，同比上升1.54%；归母净利润-2186.76万元，同比下降274.98%；扣非净利润-4878.53万元，同比下降36.95%；其中2026年第二季度，公司单季度主营收入7076.41万元，同比上升2.07%；单季度归母净利润-2149.02万元，同比下降232.98%；单季度扣非净利润-3740.17万元，同比下降79.66%；负债率5.23%，投资收益2206.28万元，财务费用350.16万元，毛利率45.82%。财报数据概要请见下图:本文数据来源于*ST明德2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662895580","title":"*ST明德(002932.SZ)：暂未直接开展脑机接口业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2662895580","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662895580?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:57","pubTimestamp":1787842623,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨*ST明德(002932.SZ)在投资者互动平台表示，公司目前聚焦主业发展，暂未直接开展脑机接口业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","MNTL","IBRN","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700545","title":"*ST明德：关于现金使用策略，公司始终兼顾经营需求、战略发展及全体股东利益","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700545?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835154,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司虽然完成了回购，但同时股价再创历史新低，公司手握丰厚现金，为什么不进一步回购从而维护股东利益？*ST明德回复：尊敬的投资者您好，关于现金使用策略，公司始终兼顾经营需求、战略发展及全体股东利益，未来资金运用将综合评估业务拓展、投资并购及股东回报等要素。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700665","title":"*ST明德：以数据为核心、AI医疗技术为引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700665?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835152,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司当前检测产品的研发中，是否有与人工智能技术的结合与开展？请介绍。*ST明德回复：尊敬的投资者您好，未来公司将以数据为核心、AI医疗技术为引擎，深耕急危重症与感染等应用场景的需求，与生态合作伙伴协同，联动院外健康管理全场景，打通“精准诊断-数字协同-院内场景化智慧诊疗-院外监测及预防康复”全链条，打造AI赋能、全周期覆盖的医疗健康服务生态，推动健康业务高质量创新发展。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700656","title":"*ST明德：已制定《2026年度估值提升计划》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700656?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835152,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德08月26日在投资者关系平台上答复投资者关心的问题。同时，公司已制定《2026年度估值提升计划》，拟通过提升经营质量、开展投资并购、持续股份回购、适时开展中长期激励计划、优化信息披露与投资者关系管理等举措，提升公司投资价值和股东回报能力，推动公司投资价值合理反映公司质量，增强投资者信心、维护全体股东利益，促进公司高质量发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700689","title":"*ST明德：公司已于6月完成股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700689?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835140,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司总经理提到长期看好公司发展，为什么个人在公司股价是每股现金资产7折的时候，不拿出实质性的行动来增持？包括贵司管理层，具体行动呢？请介绍*ST明德回复：尊敬的投资者您好，公司总经理长期看好公司发展，管理层正稳步推进各项发展规划。公司已于6月完成股份回购计划。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700650","title":"*ST明德：公司长期聚焦体外诊断主业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700650?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835139,"startTime":"0","endTime":"0","summary":"*ST明德回复：尊敬的投资者您好，公司长期聚焦体外诊断主业发展，对于产业链相关的各类投资并购机会，会基于战略发展、协同价值、财务回报等维度保持常态化观察与研究。关于回购股份注销，公司已分别于2024年和2026年开启股份回购，后续将综合市场情况、股东建议等因素统筹研判相关计划，如有变动将及时履行审议披露程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700657","title":"*ST明德：公司正逐步实现从体外诊断产品供应商向智慧诊疗一体化解决方案服务商的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700657?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835136,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：两单并购落地后，对于公司手握40亿元货币资产来说，似乎金额微小属于小打小闹的并购，公司单凭这两个公司能过扭转经营格局吗？公司实控人对公司未来的发展最终定位如何？*ST明德回复：尊敬的投资者您好，公司正逐步实现从体外诊断产品供应商向智慧诊疗一体化解决方案服务商的战略转型。公司将持续关注产业链上下游具备协同价值的投资并购机会，结合发展战略综合研判筛选。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703431","title":"*ST明德(002932)7月31日股东户数1.48万户，较上期减少1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703431","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703431?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:11","pubTimestamp":1787825495,"startTime":"0","endTime":"0","summary":"证券之星消息，近日*ST明德披露，截至2026年7月31日公司股东户数为1.48万户，较7月20日减少166.0户，减幅为1.11%。在医疗器械行业个股中，*ST明德股东户数低于行业平均水平，截至7月31日，医疗器械行业平均股东户数为2.12万户。从股价来看，2026年7月20日至2026年7月31日，*ST明德区间涨幅为3.84%，在此期间股东户数减少166.0户，减幅为1.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776963","title":"*ST明德：现阶段不存在出让上市公司控制权的相关考量与筹划安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662776963?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:18","pubTimestamp":1787815100,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司董事长兼实控人，是否有出让控制权的考量？*ST明德回复：尊敬的投资者您好，实控人长期看好公司发展，现阶段不存在出让上市公司控制权的相关考量与筹划安排。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662277695","title":"*ST明德：整合安排详见公司于《武汉明德生物科技股份有限公司重大资产购买报告书》中披露的相关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2662277695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662277695?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:18","pubTimestamp":1787815100,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：必凯尔成功落地，实现100%控股，公司管理层将如何协同该公司的新发展？请介绍一二。谢谢。*ST明德回复：尊敬的投资者您好，整合安排详见公司于《武汉明德生物科技股份有限公司重大资产购买报告书》中披露的相关内容，后续情况请关注公司公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776658","title":"*ST明德：公司重点研发项目及进展请查阅公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662776658?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:12","pubTimestamp":1787814741,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，年报显示公司2023-2025年研发支出分别为1.41亿元、1.1亿元、8577万元，属于持续高强度研发投入的状态。请公司介绍研发进展以及重点研发项目有哪些。谢谢。*ST明德回复：尊敬的投资者您好，公司重点研发项目及进展请查阅公司定期报告，公司将继续坚持自主创新，推动产品技术升级，增强核心竞争优势。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776656","title":"*ST明德：公司研发支出采用费用化处理是公司基于会计谨慎性原则的账务处理","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662776656?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:12","pubTimestamp":1787814741,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：明德生物近三年研发投入资本化率均为0%，所有研发支出均费用化处理，请问是该财务处理，是说明研发无形成成果的表现吗？为何财务处理如此谨慎。谢谢。*ST明德回复：尊敬的投资者您好，公司研发支出采用费用化处理是公司基于会计谨慎性原则的账务处理，并非研发无法形成成果，公司每年均有专利、新品等研发产出。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766517","title":"*ST明德：稳步推进对湖南蓝怡治理、财务、业务、供应链及团队一体化整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766517?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:09","pubTimestamp":1787814555,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：成功并购湖南蓝怡后，明德目前对该公司有哪些协同以及赋能发展的举措？请介绍。*ST明德回复：尊敬的投资者您好，目前公司正稳步推进对湖南蓝怡治理、财务、业务、供应链及团队一体化整合，有序落地各阶段工作，充分释放协同价值。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766387","title":"*ST明德：本次收购前必凯尔累计向原股东分红近2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766387","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766387?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:09","pubTimestamp":1787814555,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：并购必凯尔后，但是必凯尔因为分红减少了2亿元的日子资金，他们如何还能够达成之前的效益,公司是否有考虑到这个变动对必凯尔经营的影响？谢谢。*ST明德回复：尊敬的投资者您好，本次收购前必凯尔累计向原股东分红近2亿元，系必凯尔被原股东控股后多年经营期间分次实施，不会对必凯尔正常生产经营产生影响。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766347","title":"*ST明德：控股子公司的营业收入全部计入合并报表营业收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766347?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:09","pubTimestamp":1787814555,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司年初收购并持有蓝怡（湖南）51%股权，年报并表的时候蓝怡（湖南）的营业收入是按51%还是按100%并入公司年报，请说明下谢谢*ST明德回复：尊敬的投资者您好，根据企业会计准则相关规定，控股子公司的营业收入全部计入合并报表营业收入。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662637776","title":"*ST明德：公司正根据整体战略规划，对包括品牌展示在内的资源配置进行统筹优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2662637776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662637776?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:09","pubTimestamp":1787814553,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司官网尚未有蓝怡公司医疗产品的介绍，既然是个专精特新小巨人企业，希望及时发布宣传*ST明德回复：尊敬的投资者您好，公司正根据整体战略规划，对包括品牌展示在内的资源配置进行统筹优化，后续将依据整合进度适时完善产品展示体系。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776378","title":"*ST明德：公司现有糖化血红蛋白系列产品主要面向医疗机构、体检中心等专业机构用户","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662776378?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:07","pubTimestamp":1787814437,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有糖化血红蛋白系列产品，相关产品是基于高效液相色谱 方法对糖化血红蛋白进行检测，可以反映糖尿病患者近 8-12 周的血糖控制水平，该方法是国际公认的糖尿病检测“金标准”。请问以上产品主要是医院用器械还是家用的？*ST明德回复：尊敬的投资者您好，公司现有糖化血红蛋白系列产品主要面向医疗机构、体检中心等专业机构用户。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776537","title":"*ST明德：呼吸道相关检测秋冬季需求相对较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662776537?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:07","pubTimestamp":1787814436,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST明德(002932)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司所处的行业是否存在季节周期？是否存在淡旺季的不同？一般是哪个季节是旺季？谢谢解答。*ST明德回复：尊敬的投资者您好，体外诊断行业不同细分领域季节性存在差异：常规诊断业务季节性不显著，呼吸道相关检测受疾病流行周期影响，秋冬季需求相对较高。公司业务涵盖多品类产品，各季度收入存在正常波动。具体请以定期报告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788908413795,"stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0562},{"period":"3month","weight":0.0176},{"period":"6month","weight":-0.1644},{"period":"1year","weight":-0.2093},{"period":"ytd","weight":-0.1867}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉明德生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14841人(较上一季度减少1.11%)","perCapita":"10517股","listingDate":"2018-07-10","address":"湖北省武汉市江夏区东湖新技术开发区九龙中路77号武汉明德生物科技产业园(一期)(全部自用)1栋1单元1层1号C区","registeredCapital":"23252万元","survey":" 武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公司的主要产品是体外诊断试剂、诊断仪器。","listedPrice":20.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"*ST明德(002932)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供*ST明德(002932)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"*ST明德,002932,*ST明德股票,*ST明德股票老虎,*ST明德股票老虎国际,*ST明德行情,*ST明德股票行情,*ST明德股价,*ST明德股市,*ST明德股票价格,*ST明德股票交易,*ST明德股票购买,*ST明德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"*ST明德(002932)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供*ST明德(002932)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}